Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials

Wongsa, Chamard; Phinyo, Phichayut; Sompornrattanaphan, Mongkhon; Krikeerati, Thanachit; Lumkul, Lalita; Thongngarm, Torpong

doi:10.1016/j.jaip.2022.01.046

Cited by 10 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No anaphylaxis cases were reported in the group undergoing HDM SLIT. 11 Compared with the adult patients in the present study, the pediatric patients had a higher frequency of SARs; however, the cohort size of the pediatric cohort was very small, allowing only conjecture regarding the possible reasons.…”

Section: Resultsmentioning

confidence: 61%

Real-world assessment of anaphylaxis and eosinophilic esophagitis with 12 SQ house dust mite SLIT-tablet sublingual immunotherapy

Zeiger,

Schatz,

Pomichowski

et al. 2024

Journal of Allergy and Clinical Immunology: Global

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 61%

Real-world assessment of anaphylaxis and eosinophilic esophagitis with 12 SQ house dust mite SLIT-tablet sublingual immunotherapy

Zeiger,

Schatz,

Pomichowski

et al. 2024

Journal of Allergy and Clinical Immunology: Global

View full text Add to dashboard Cite

“…Studies have confirmed the efficacy and safety of SLIT in children with AR coupled with single and multiple allergies and can achieve long-term efficacy (13)(14)(15). A study has shown that SLIT can effectively reduce the dose of inhaled corticosteroids (ICS) in adolescents with mild to moderate allergic asthma, with a good safety profile (16). Additionally, SLIT also improves disease severity and prevents new sensitization in children with an atopic dermatitis allergy to dust mites (17).…”

Section: Discussionmentioning

confidence: 96%

Serum vitamin D3 deficiency can affect the efficacy of sublingual immunotherapy in children with allergic rhinitis: a retrospective cohort study

Li¹,

Cui²,

Zhang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Sublingual immunotherapy (SLIT) is effective and convenient for many allergic patients but it is still ineffective for many children with allergic rhinitis (AR). In previous studies, most of the patients with poor efficacy of SLIT used the method of individualized adjustment of drug dosage. Currently, there are few reports on the relationship between serum vitamin D 3 level and the efficacy of SLIT.Methods: In this study, 153 patients with AR who received SLIT were selected as the study objects. All patients collected serum for vitamin D 3 test before treatment. The clinical characteristics of the patients were collected, and all patients were regularly followed up for at least 6 months. The improvement rates were assessed according to the combined symptom medication score (CSMS). A receiver operating characteristic (ROC) curve was drawn, and the optimal cut-off point was determined according to the Youden index.Univariate and multivariate logistic regression were used to analyze the relationship between serum vitamin D 3 and SLIT efficacy. The odds ratios (ORs) and 95% confidence intervals (CIs) were computed by logistic regression.Results: Of 153 AR patients, 101 patients entered the final statistical analysis. According to CSMS, 29.7% of patients in low response (LR) group. The mean vitamin D 3 level was (20.42±7.48) ng/mL. The optimal cutoff point for vitamin D 3 was 22.25 ng/mL. Univariate logistic regression analysis of SLIT efficacy showed that whether the patient also had a food allergy (P<0.001) or asthma (P=0.011), whether they used acarid products (P=0.002), and whether vitamin D 3 is sufficient (P=0.001) were significantly related to the efficacy of SLIT. Multivariate logistic regression analysis showed that after adjusting for whether the patient also had asthma and whether they had used acarid products, whether the patient also had a food allergy (OR: 12.13, 95% CI: 3.57-41.18, P<0.001) and whether vitamin D 3 is sufficient (OR: 22.21, 95% CI: 4.04-122.30, P<0.001) were independent factors affecting the efficacy of SLIT.Conclusions: Serum Vitamin D 3 deficiency can affect the efficacy of SLIT in children with AR. This study provided a new therapeutic approach for SLIT patients with poor efficacy.

show abstract

“…A randomized, placebo-controlled trial looking at efficacy and safety of HDM SLIT-T in 743 North American adolescents and adults found mostly mild to moderate local reactions (84% of participants), most commonly throat irritation, oral pruritus, and ear pruritus with only three adverse reactions requiring epinephrine and no systemic reactions reported [24]. The safety of HDM SLIT-T in patients with asthma appears to be similar to patients without asthma [25 ▪ ]. HDM clinical trials in children less than 12 years of age have not been completed, thus the safety profile in that age group is not yet established.…”

Section: Sublingual Immunotherapy Safetymentioning

confidence: 99%

Safety of allergen immunotherapy in children

Schmidlin,

Bernstein

2023

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of review The current review discusses allergen immunotherapy (AIT) safety in children. Recent findings AIT is a well tolerated and effective treatment for pediatric allergic conditions. While mostly well tolerated, severe reactions and near fatal reactions may occur with subcutaneous immunotherapy (SCIT) once in every 160 000 visits. Sublingual immunotherapy (SLIT) is associated more with local side effects, but severe systemic reactions, including anaphylaxis, have been rarely reported. Providing informed consent, recognizing risk factors for severe systemic reactions, such as severe or uncontrolled asthma, and mitigating the risk of severe reactions are important components to improving the safety of AIT. Summary Overall, AIT is well tolerated in children, and data suggest that the incidence of systemic reactions in children receiving SCIT is no less than mixed populations of adult and pediatric patients. SLIT carries less risk for systemic reactions, and local oral site-application reactions are usually mild and resolve within 15 days of treatment.

show abstract

Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials

Cited by 10 publications

References 35 publications

Real-world assessment of anaphylaxis and eosinophilic esophagitis with 12 SQ house dust mite SLIT-tablet sublingual immunotherapy

Real-world assessment of anaphylaxis and eosinophilic esophagitis with 12 SQ house dust mite SLIT-tablet sublingual immunotherapy

Serum vitamin D3 deficiency can affect the efficacy of sublingual immunotherapy in children with allergic rhinitis: a retrospective cohort study

Safety of allergen immunotherapy in children

Contact Info

Product

Resources

About